AI assistant
Sending…
Aclaris Therapeutics, Inc. — Director's Dealing 2021
Nov 22, 2021
33670_dirs_2021-11-22_782bf175-b2df-4c8c-bec1-3b0f644a6f20.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2021-03-11
Reporting Person: Ali-Jackson Kamil (Chief Legal Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-11 | Common Stock | G | 7500 | $0.00 | Disposed | 114696 | Direct |
More from Aclaris Therapeutics, Inc.
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Regulatory Filings
2026
Apr 28
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 26
Major Shareholding Notification
2026
Mar 17
Director's Dealing
2026
Mar 3
Annual Report
2026
Feb 26
Regulatory Filings
2026
Feb 26